1. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: A review of the diagnosis, treatment, and clinical implications. Pediatrics 2005;115(6):1734-1746.

2. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyper-activity disorder. N Engl J Med 1999;340(1):40-46.

3. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999;340(10):780-788.

4. Voeller KKS. Attention-deficit hyperactivity disorder (ADHD). J Child Neurol 2004;19:798-814.

5. Herrerias CT, Perrin JM, Stein MT. The child with ADHD: Using the AAP clinical practice guideline. Am Fam Physician 2001;63(9):1803-1810.

6. Biederman J, Faraone S. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-248.

7. Centers for Disease Control and Prevention. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder—United States, 2003. MMWR 2005;54:842-847.

8. Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med 2005;352:165-173.

9. Elliott H. Attention deficit hyperactivity disorder in adults: A guide for the primary care physician. South Med J 2002;95:736-742.

10. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactiv-ity Disorder and Committee on Quality Improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-1044.

11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Rev. Washington, DC: American Psychiatric Press, 2000:39-134.

12. Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyper-activity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.

13. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999(Dec);56(12):1073-1086.

14. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(Suppl 2):26S-49S.

15. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A doubleblind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-976.

16. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-185.

17. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyper-activity disorder: Overview of the evidence. Pediatrics 2005;115:749-757.

18. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 2001;108(5):E83.

19. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphen-idate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41(7):776-784.

20. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901.

21. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002;110(6):E75.

22. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 2008;165(6):721-730.

23. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, doubleblind comparison trial. Aust NZJ Psychiatry 2007;41(3):222-230.

24. Belle DJ, Ernest S, Sauer J, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002;42:1219-1227.

25. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002;67(2):149-156.

26. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001;[email protected]):307-314.

27. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288.

28. Tallian K. Pharmacotherapy of ADHD. In: Schumock G, Brundage D, Chapman M, et al., eds. Pharmacotherapy Self-Assessment Program, 5th ed. Pediatrics II. Kansas City, MO: American College of Clinical Pharmacy, 2006:275-297.

29. Amitai Y, Frischer H. Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:54-60.

30. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003;42:886-894.

31. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005;3:5.

32. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the U.S.: Excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005;21(2):195-205.

33. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: Scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42(9):1015-1037.

34. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for Attention Deficit/Hyper-activity Disorder: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407-2423.

35. Perrin JM, Friedman RA, KnilansTK, et al. Cardiovascular monitoring and stimulant drugs for Attention-Deficit/Hyperactivity Disorder. Pediatrics 2008; 122:451-453.

36. ECGs before stimulants in children. Med Lett Drugs Ther 2008 Jul 28;50(1291):60.


43 Diabetes Mellitus

John T. Johnson, Susan Cornell, and William E. Wade


Understanding And Treating ADHD

Understanding And Treating ADHD

Attention Deficit Disorder or ADD is a very complicated, and time and again misinterpreted, disorder. Its beginning is physiological, but it can have a multitude of consequences that come alongside with it. That apart, what is the differentiation between ADHD and ADD ADHD is the abbreviated form of Attention Deficit Hyperactive Disorder, its major indications being noticeable hyperactivity and impulsivity.

Get My Free Ebook

Post a comment